Form 4: Zomedica Director Acquires 1.8 Million Stock Appreciation Rights

Zomedica Corp. director Robert Cohen acquired 1,823,107 stock appreciation rights on November 11, 2024.

Summary

• Robert Cohen, a director at Zomedica Corp., acquired 1,823,107 stock appreciation rights on November 11, 2024.
• These rights have an exercise price of $0.13.
• The stock appreciation rights are exercisable starting November 10, 2025, and expire on November 10, 2034.
• The underlying security for these rights is 1,823,107 shares of Zomedica common stock.

Sentiment

Score: 6

Explanation: The transaction is a routine filing and doesn't indicate a significant positive or negative sentiment. It's a standard part of executive compensation.

Positives

• The acquisition of stock appreciation rights by a director could be seen as a positive sign of confidence in the company's future performance.

Industry Context

This type of transaction is common for directors and executives as part of their compensation and incentive packages.

Comparison to Industry Standards

• Stock appreciation rights are a common form of equity compensation used by publicly traded companies to align the interests of management with those of shareholders.
• The terms of these rights, such as the exercise price and vesting schedule, are generally consistent with industry practices.

Stakeholder Impact

• The acquisition of stock appreciation rights by a director may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Stock Appreciation Rights, Zomedica, Director, Robert Cohen, Equity, Transaction, Beneficial Ownership